Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws EU filing for canakinumab

The decision is a further setback for this expansion in the use of canakinumab, which Novartis already markets as an inflammatory disease treatment under the brand name Ilaris.

Latest news

Novartis culls pipeline to focus on most transformative science

It recently hit problems with one of its most important late-stage programmes when the FDA refused to accept the filing of anti-inflammatory drug canakinumab (Ilaris) in cardiovascular risk reduction.
Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.
CV data sets up Novartis' Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events. Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option to ... The CANTOS study showed that the active ingredient in
Novartis' Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever Syndrome conditions. ... Paul Hudson, Novartis
Novartis wins childhood arthritis indication for Ilaris in EU

Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU following its approval for the treatment of a rare form of childhood arthritis. ... The European Commission (EC) gave its final assent to Ilaris for the treatment

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Medical Writer: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Subscribe to our email news alerts

PMHub

Add my company

SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...